Publications by authors named "Takuya Tomomatsu"
Article Synopsis
- Perioperative FEC therapy is a common treatment for breast cancer, but over 20% of patients experience febrile neutropenia (FN), which pegfilgrastim is often used to prevent.
- A study on pegfilgrastim's long-term safety found no significant differences in blood cell counts or long-term effects after one year of use.
- Pegfilgrastim administration significantly reduced the incidence of FN (6.5% with pegfilgrastim vs. 22.8% without), indicating it can be safely used for one year in breast cancer patients undergoing chemotherapy.
Article Synopsis
- A study investigated the costs and survival outcomes associated with pegfilgrastim prophylaxis for febrile neutropenia (FN) in breast cancer patients undergoing chemotherapy in Japan.
- The pegfilgrastim group had higher median total medical costs compared to the non-pegfilgrastim group but did not show a significant difference in FN hospitalization costs.
- Despite increased costs, there was no significant difference in 3-year overall survival rates between the two groups, suggesting pegfilgrastim should be used selectively based on individual FN risk factors rather than routinely.
Background: Female sex and younger age are reported risk factors for chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.
Methods: This retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline-based chemotherapy for breast cancer between January 2018 and June 2020.
Hypertension is one of the main side effects of ramucirumab(RAM)plus paclitaxel(PTX)therapy. Although dihydropyridine calcium channel blockers(D-CCBs)are considered to cause drug-drug interactions with PTX based on the inhibition of cytochrome P450, D-CCBs are often administered to patients receiving RAM plus PTX therapy in clinical practice. We retrospectively studied the actual usage of antihypertensive drugs in 133 advanced or recurrent gastric cancer patients who received RAM plus PTX therapy.
View Article and Find Full Text PDFThis retrospective study aimed to evaluate the effect of the antiemetic drug olanzapine(OLZ)on blood sugar levels in patients treated with adjuvant or neoadjuvant chemotherapy(AC: doxorubicin plus cyclophosphamide or CEF: cyclophosphamide plus epirubicin plus fluorouracil) for breast cancer. Here, we evaluated the frequency of diabetes(postprandial blood sugar: PBS≥200 mg/dL)and the change in PBS in 149 patients who were prescribed OLZ between September 2016 and August 2017 at our hospital. No diabetic patients were identified during the observation period(median: 3 cycles of chemotherapy).
View Article and Find Full Text PDF